Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086022 | 0.82 | CCR2 (0.50) | CCR2CCR9PTGER4PTGDRMAPT | |
| SCHEMBL4098695 | 0.80 | CCR2 (0.51) | CCR2PTGESP2RX3CCR9 | |
| SCHEMBL5750477 | 0.77 | CCR2 (0.62) | CCR2PTGESCCR9 | |
| SCHEMBL4086016 | 0.74 | CCR2 (0.49) | CCR2PTGESCCR9PTGER4PTGDR | |
| SCHEMBL4094156 | 0.72 | PTGES (0.43) | CCR2PTGESP2RX3LMNAMAPT | |
| SCHEMBL6091132 | 0.70 | PTGES (0.55) | CCR2PTGESP2RX3 | |
| SCHEMBL4086613 | 0.69 | MAPT (0.50) | LMNAMAPT | |
| SCHEMBL6093568 | 0.69 | PTGES (0.54) | CCR2PTGESP2RX3 | |
| SCHEMBL5738720 | 0.69 | NOD2 (0.49) | CCR2PTGESP2RX3MAPTPLA2G2A | |
| SCHEMBL6091214 | 0.69 | PTGES (0.51) | CCR2PTGESP2RX3PTGER4PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | CCR2 1118/4885PTGES 3/4885P2RX3 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.